To achieve continued double digit growth and mitigate risks in R&D and manufacturing, pharma companies must gather actionable intelligence that will enable them to move rapidly from quantity-based, fee-for-service model to outcomes based contracts and adopt new digital platforms to deliver targeted therapeutics and improve profitability in a transformed healthcare market.
Frost & Sullivan’s Pharma 4.0 Research Program
The Pharma 4.0 program is centric to capture some of the most transformative pivots in the precision medicine landscape. It enables companies to stay ahead of the shift from small molecules to biologics, decode risks in contract research and manufacturing and embrace digital strategies to increase the value of new therapies. The team offers expert coverage on a variety of issues including portfolio management tools to expand in biosimilars, cell therapy and partnerships with Life Sciences IT companies to maximize operational excellence.
Frost & Sullivan’s expertise in pharma 4.0 research and consulting includes work in the following strategic and operational areas
Contract Development & Manufacturing
Due to the growing demand for biologics & biosimilars, Contract Research Organizations (CRO) and Contract Development Manufacturing Organizations’ (CDMO) expertise in drug development will further disrupt the in-house–outsourced balance. Our research coverage includes outsourcing services, bio-processing platforms, and single-use technologies.
Regenerative medicine is witnessing a surge in R&D activities with large-scale efforts from small to mid-segment companies with targeted therapeutic focus. Whilst the market is loaded with dermatological and musculoskeletal therapies, the approval of Kymriah by Novartis, and Yescarta by Gilead have brought in a fresh lease of hope for previously unresolved cancer cases. Our research coverage includes Anti-Aging Therapies & Services and Cell & Gene Therapies.
The emergence of value-based reimbursement models and healthcare consumerism has provided a strong impetus to precision medicine. Investments across complex immunotherapies, alongside a strong potential for orphan drugs, are shifting the market paradigm towards M&A driven growth. Our research coverage includes immuno oncology therapies, bioengineered vaccines, cardiometabolic therapies, neurodegenerative therapies, and biobetters.
Life Sciences IT
The increasing importance of patient centricity and digital continuity is driving higher utilization of big data analytics, cloud and AI-based platforms across industry value chain. This is evident from the recent partnerships forged by big pharmaceutical companies including GSK, Sanofi, Novartis, and Roche, with start-ups. We have identified 4 distinct pillars: Smart R&D, Connected Patient, Flexible Manufacturing and Digital Pharmacy to capture these trends. Our research coverage includes real-world evidence services, clinical trials data patient recruitment & monitoring solutions and the digital transformation of the pharma industry.
Book a complimentary one-hour Growth Pipeline Dialog™ session with our Healthcare & Life Sciences experts.
Greg Caressi is responsible for Frost & Sullivan’s Healthcare and Life Sciences practice, which includes Digital Health, Life Sciences, Medical Imaging & Informatics, and Advanced Medical Technologies. He engages with industry leaders across the globe regarding their technology needs and gaps, and leverages insights from our research to identify growth opportunities and needed solution capabilities for healthcare stakeholders, including healthcare providers, payors, government agencies, medical technology vendors and individual consumers.
Reenita Das currently serves as Healthcare and Life Sciences’ Partner and Senior Vice President and is the first woman Partner at Frost & Sullivan, driving the global research vision and strategy for the firm as well as commercial opportunities within the healthcare practice. She has lived and worked in over 10 countries in the world, focusing on finding solutions to healthcare challenges and implementing growth change strategies. She recently got voted the top 100 women in Femtech and Healthtech. Reenita’s focus is on how healthcare will operate 20 years from today and she shares her vision at leading conferences and events.
She is also passionate about using digital solutions and creating gender-specific healthcare by her focus on “Femtech” and the growth opportunities from this new sector which includes advising companies on the right strategies and commercial business models to success.
Dinesh Sampath Rangaraj
With more than 24 years of industry experience, Nitin serves as Frost & Sullivan’s Global Practice Area Leader (HLS). In this role, he is dedicated to executing strategy consulting, forecasting analytics, commercial due diligence and clinical R&D projects for healthcare companies.
Nitin has a strong understanding of the dynamics in the healthcare industry and possesses domain knowledge in the life sciences space. He has advised several mid sized companies and start-ups in numerous commercial transactions and IPOs to optimize market positioning and valuation strategies.
He has led strategic initiatives with Medical Device & Life Science companies:
- Emerging markets go to market strategy , Innovative therapies portfolio analysis
- Sales, Marketing, Distribution planning
- Global Alliances, Public Private Partnerships, M&A.
- Co-innovation programs, research
Charlie leads Frost & Sullivan’s growth consulting practice in the Americas supporting clients across the healthcare technology and services ecosystem. His responsibilities include project management, business development, strategic planning and subject matter expertise, particularly in the medical devices market.
Siddharth (Sid) Shah leads the global medtech research program of the Healthcare & Life Sciences practice, and has over ten years of healthcare market research & consulting experience. In his prior life he has also conducted wet lab research in stem cells at the prestigious Johns Hopkins University. Beyond medical devices, Shah also tracks innovations in radiology artificial intelligence, diabetes, and connected devices. He holds a Master of Science in Biotechnology from the Johns Hopkins University.
Daniel leads the growth consulting practice for Healthcare & Life Sciences in the Middle East & Africa. This practice covers Healthcare Delivery & Operations, Medical Imaging & Informatics, Pharmaceuticals & Life Sciences, and Digital Health.
Daniel is a seasoned healthcare professional with more than 15 years’ experience in the healthcare industry and has extensive experience supporting clients to achieve their strategic growth objectives through Optimization, Efficiency, Quality and Cost Initiatives; Market Analysis, Customer VOC/Perception studies, Due Diligence, and Service Expansion; Healthcare Data and Analytics; Change, Program and Project Management; and, Leadership Development.
Imran has over 20 years of experience in market research and consulting, covering a range of information and communication technologies across multiple industry verticals and enterprise and consumer segments.
The Pharma 2.0 team utilizes a proven methodology that leverages Frost & Sullivan’s proprietary forecast models, access to high-quality internal and external published content, and information gained from primary research interviews. We have developed a strong network of key opinion leaders and subject matter experts who partner with us to develop futuristic insights. Most projects also leverage our proprietary market models that enable us to develop mid-range (5 year) and long range (10 year) forecasts based on inputs from primary research.